Clinical Trials Browser

Completed × Has results × dacomitinib × Clear all

NCT04609319 2025-05-31

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Completed

307 enrolled 25 charts

Thoracic

Lung Neoplasms

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04511533 2024-04-05

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Phase 4 Completed

101 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01000025 2023-08-22

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Phase 3 Completed

720 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Phase 1 Completed

110 enrolled 80 charts

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT01520870 2021-07-06

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Phase 2 Completed

49 enrolled 9 charts

CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT00768664 2021-02-09

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Phase 2 Completed

69 enrolled 18 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT00553254 2020-10-19

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Phase 2 Completed

55 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00548093 2019-05-21

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2 Completed

66 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01465802 2019-01-09

ARCHER 1042

Phase 2 Completed

236 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00818441 2019-01-08

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Phase 2 Completed

119 enrolled 12 charts

Tumor-Agnostic

Carcinoma

NCT00728468 2017-08-02

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Phase 1 Completed

16 enrolled 19 charts

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT01858389 2017-07-18

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

41 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01360554 2017-05-24

ARCHER 1009

Phase 3 Completed

878 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Phase 1 Completed

70 enrolled 50 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00769067 2015-10-07

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase 2 Completed

188 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis